Earnings summaries and quarterly performance for Azitra.
Executive leadership at Azitra.
Board of directors at Azitra.
Research analysts covering Azitra.
Recent press releases and 8-K filings for AZTR.
Azitra Adjourns Special Meeting Due to Lack of Quorum
AZTR
Proxy Vote Outcomes
Delisting/Listing Issues
- Azitra, Inc.'s Special Meeting, originally scheduled for February 6, 2026, was adjourned because a quorum was not present, with only approximately 13% of outstanding shares represented, falling short of the 33 1/3% required.
- The Special Meeting has been reconvened for March 6, 2026, at 11:00 a.m. Eastern Time, to allow for the solicitation of additional votes.
- The primary proposal for the meeting is the approval of the issuance of more than 19.99% of common stock underlying warrants, pursuant to a Securities Purchase Agreement with Alumni Capital LP dated November 24, 2025, to comply with NYSE American Company Guide Section 713(a) and 713(b).
- Stockholders as of the January 2, 2026, record date are encouraged to vote their proxies by March 6, 2026, at 10:59 a.m. Eastern Time.
7 hours ago
Azitra Adjourns Special Meeting Due to Lack of Quorum
AZTR
Proxy Vote Outcomes
Delisting/Listing Issues
- Azitra, Inc. (AZTR) adjourned its Special Meeting convened on February 6, 2026, because a quorum was not present.
- Only approximately 13% of outstanding shares entitled to vote had submitted proxies, which was less than the 33 1/3% required for a quorum.
- The Special Meeting has been reconvened for March 6, 2026, at 11:00 a.m. Eastern Time, and will be held virtually.
- The primary proposal for the reconvened meeting is the approval of issuing more than 19.99% of common stock underlying warrants, pursuant to a Securities Purchase Agreement with Alumni Capital LP.
7 hours ago
Azitra Receives Acceptance for NYSE American Listing Compliance Plan
AZTR
Delisting/Listing Issues
- Azitra, Inc. received notice on December 16, 2025, that NYSE American LLC accepted its plan to regain compliance with the exchange's continued listing standards.
- The company was previously notified on October 1, 2025, of non-compliance with the $4.0 million minimum stockholders' equity requirement, due to reported losses from continuing operations and/or net losses in three of the four most recent fiscal years.
- Azitra has until April 1, 2027, to regain compliance with the continued listing standards.
- During the plan period, Azitra will continue its listing on NYSE American, but failure to comply or make consistent progress could lead to delisting proceedings.
Dec 17, 2025, 9:15 PM
Azitra Receives NYSE American Approval for Compliance Plan
AZTR
Delisting/Listing Issues
- Azitra, Inc. received approval from NYSE American LLC for its plan to come into compliance with the Exchange's continued listing standards.
- The company was previously notified on October 1, 2025, that it was not in compliance with the minimum stockholders' equity requirement of $4.0 million.
- Azitra must regain compliance with the continued listing standards by April 1, 2027, or NYSE Regulation staff will initiate delisting proceedings.
- This notice has no immediate effect on the listing or trading of Azitra's common stock on the Exchange.
Dec 17, 2025, 9:10 PM
Azitra, Inc. Announces $1.5 Million Private Placement
AZTR
Equity Offering
Proxy Vote Outcomes
- Azitra, Inc. announced a private placement on November 24, 2025, with a single institutional investor to raise approximately $1.5 million in gross proceeds.
- The offering involves the purchase of 4,687,500 shares of common stock (or pre-funded warrants) and warrants to purchase an additional 4,687,500 shares of common stock.
- The combined effective offering price for each share of common stock (or pre-funded warrant) and accompanying warrant is $0.32, with the warrants having an exercise price of $0.32 per share.
- The offering is expected to close on or about November 25, 2025, and the warrants will be exercisable upon shareholder approval, which the company plans to seek by February 6, 2026.
Nov 25, 2025, 10:02 PM
Azitra Announces $1.5 Million Private Placement
AZTR
New Projects/Investments
- Azitra, Inc. has entered into a securities purchase agreement for a private placement with a single institutional investor.
- The offering includes the sale of 4,687,500 shares of common stock (or pre-funded warrants) and warrants to purchase up to an aggregate of 4,687,500 shares of common stock.
- The combined effective offering price for each share/warrant is $0.32, with estimated gross proceeds of approximately $1.5 million before deducting fees and expenses.
- The transaction is expected to close on or about November 25, 2025.
Nov 24, 2025, 2:00 PM
Azitra, Inc. Announces Q3 2025 Results and Business Updates
AZTR
Earnings
New Projects/Investments
- Azitra, Inc. reported a net loss of $2.8 million for the quarter ended September 30, 2025, compared to $1.0 million for the comparable period in 2024.
- As of September 30, 2025, the company had $1.4 million in cash and cash equivalents.
- The company initiated dosing of the first patient in its Phase 1/2 trial for the ATR-04 program in August 2025 and presented positive preclinical data for the ATR-01 program.
- Azitra raised $2.8 million in gross proceeds through an established equity line of credit.
Nov 12, 2025, 10:15 PM
Azitra, Inc. Announces Q3 2025 Results and Business Updates
AZTR
Earnings
New Projects/Investments
- Azitra, Inc. reported a net loss of $2.8 million for the quarter ended September 30, 2025, compared to $1.0 million for the comparable period in 2024.
- For Q3 2025, Research and Development (R&D) expenses were $1.2 million and General and Administrative (G&A) expenses were $1.6 million.
- As of September 30, 2025, the company held $1.4 million in cash and cash equivalents.
- During the quarter, Azitra dosed the first patient in its Phase 1/2 trial for the ATR-04 program and raised $2.8 million in gross proceeds through an equity line of credit.
Nov 12, 2025, 10:01 PM
Azitra, Inc. Addresses False Report Regarding Securities Sale
AZTR
- Azitra, Inc. (AZTR) announced on November 7, 2025, that a circulating report claiming the company priced a $44 million registered direct offering is false and should not be relied upon.
- The company urges investors to rely only on information formally issued through its official channels.
- Azitra is taking steps to identify the source of the false report.
Nov 7, 2025, 11:00 AM
Azitra receives NYSE American notice of non-compliance
AZTR
Delisting/Listing Issues
- Azitra, Inc. received a notice from NYSE American LLC on October 1, 2025, indicating non-compliance with continued listing standards under Section 1003(a)(ii).
- The non-compliance stems from having stockholders' equity of $2.2 million as of June 30, 2025, which is below the required $4 million, and having reported losses in three of its four most recent fiscal years.
- Azitra has until October 31, 2025, to submit a plan to regain compliance, with a target compliance date of April 1, 2027.
- The notice has no immediate effect on the listing or trading of Azitra's common stock.
Oct 3, 2025, 8:59 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more